Yuling H. Shi
1278 Baode Road
Jing'an, 200443, China
Jing'an, 200443, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 166 publications
Author Correction: IL-17D-induced inhibition of DDX5 expression in keratinocytes amplifies IL-36R-mediated skin inflammation.
Journal: Nature immunology
Published: August 18, 2026
Clinical predictors of early treatment response across systemic therapies in psoriasis: a prospective cohort study.
Journal: The Journal of dermatological treatment
Published: August 13, 2026
Safety and effectiveness of omalizumab for chronic spontaneous urticaria inadequately controlled with H1 antihistamines in Chinese adolescents: a real-world, prospective, multicenter study.
Journal: The Journal of dermatological treatment
Published: July 13, 2026
Response to the letter by Ghanim et al, "Comment on Gao et al.'s 'A Multicenter, Randomized, Double-blinded, Placebo-Controlled Phase III Trial to Evaluate Efficacy and Safety of Picankibart in Moderate-to-Severe Plaque Psoriasis'".
Journal: Journal of the American Academy of Dermatology
Published: June 26, 2026
Efficacy and Safety of the First Adalimumab Biosimilar in Chinese Children with Severe Plaque Psoriasis: The PISCES Study, a Multicenter Prospective Study.
Journal: Dermatology and therapy
Published: June 02, 2026
International expert consensus on transdermal drug delivery technologies in dermatology.
Journal: JAAD international
Published: April 30, 2026
Integrated transcriptomic and tissue-validation analyses identify palmitoylation-associated biomarkers linked to sphingolipid metabolism and immune remodeling in psoriasis.
Journal: Frontiers in immunology
Published: April 15, 2026
Development of Predictive Models for NB-UVB Treatment Efficacy and Safety in Psoriasis.
Journal: Psoriasis (Auckland, N.Z.)
Published: March 17, 2026
Comprehensive Metabolomic Profiling of Skin Lesions from Psoriasis Patients Reveals Disease Signatures.
Journal: International journal of biological sciences
Published: March 08, 2026
Improvements in clinical and patient-reported outcomes and durability of response with the targeted oral peptide icotrokinra in adolescents with moderate-to-severe plaque psoriasis: One-year results from the ICONIC-LEAD randomized controlled trial.
Journal: Journal of the American Academy of Dermatology
Published: February 20, 2026
Development and validation of a prediction model for primary non-response to IL-17A inhibitors in psoriasis.
Journal: Frontiers in medicine
Published: November 10, 2025
Last Updated: 09/26/2026